https://ir.vyometx.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_d024ecc7eca47b6f52a71f1586e4b046/vyometx/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.vyometx.com/news-events/press-releases/detail/110/vyome-receives-uspto-notice-of-allowance-for-u-s-patent-covering-vt-1908-its-novel-topical-mycophenolate-program-targeting-the-20-billion-ocular-inflammation-market Mon, 05 Oct 26 08:00:00 -0400 https://ir.vyometx.com/news-events/press-releases/detail/110/vyome-receives-uspto-notice-of-allowance-for-u-s-patent-covering-vt-1908-its-novel-topical-mycophenolate-program-targeting-the-20-billion-ocular-inflammation-market https://ir.vyometx.com/news-events/press-releases/detail/109/vyome-appoints-experienced-public-company-finance-executive-jerry-leonard-as-chief-financial-officer Mon, 14 Sep 26 08:00:00 -0400 https://ir.vyometx.com/news-events/press-releases/detail/109/vyome-appoints-experienced-public-company-finance-executive-jerry-leonard-as-chief-financial-officer https://ir.vyometx.com/news-events/press-releases/detail/108/vyome-holdings-reports-second-quarter-2026-results-highlighted-by-advancement-of-lead-vt-1953-program-pipeline-expansion-and-strong-balance-sheet Tue, 25 Aug 26 08:00:00 -0400 https://ir.vyometx.com/news-events/press-releases/detail/108/vyome-holdings-reports-second-quarter-2026-results-highlighted-by-advancement-of-lead-vt-1953-program-pipeline-expansion-and-strong-balance-sheet https://ir.vyometx.com/news-events/press-releases/detail/107/vyome-granted-chinese-patent-strengthening-immuno-inflammation-portfolio Wed, 01 Jul 26 08:00:00 -0400 https://ir.vyometx.com/news-events/press-releases/detail/107/vyome-granted-chinese-patent-strengthening-immuno-inflammation-portfolio https://ir.vyometx.com/news-events/press-releases/detail/106/vyome-holdings-reports-first-quarter-2026-results-with-key-fda-filings-and-strong-balance-sheet Thu, 28 May 26 08:00:00 -0400 https://ir.vyometx.com/news-events/press-releases/detail/106/vyome-holdings-reports-first-quarter-2026-results-with-key-fda-filings-and-strong-balance-sheet https://ir.vyometx.com/news-events/press-releases/detail/105/vyome-strikes-deal-with-impetis-biosciences-opening-a-~57b-market-opportunity Tue, 12 May 26 08:00:00 -0400 https://ir.vyometx.com/news-events/press-releases/detail/105/vyome-strikes-deal-with-impetis-biosciences-opening-a-~57b-market-opportunity https://ir.vyometx.com/news-events/press-releases/detail/85/vyome-presents-transformational-vt-1953-phase-2-clinical-study-data-at-prestigious-aacr-2026 Wed, 22 Apr 26 08:00:00 -0400 https://ir.vyometx.com/news-events/press-releases/detail/85/vyome-presents-transformational-vt-1953-phase-2-clinical-study-data-at-prestigious-aacr-2026 https://ir.vyometx.com/news-events/press-releases/detail/86/vyome-to-present-compelling-phase-2-clinical-data-on-vt-1953-for-treatment-of-mfw-at-aacr-2026 Mon, 06 Apr 26 08:00:00 -0400 https://ir.vyometx.com/news-events/press-releases/detail/86/vyome-to-present-compelling-phase-2-clinical-data-on-vt-1953-for-treatment-of-mfw-at-aacr-2026 https://ir.vyometx.com/news-events/press-releases/detail/87/vyome-reports-transformational-2025-results-company-well-positioned-for-breakout-phase Thu, 26 Mar 26 08:00:00 -0400 https://ir.vyometx.com/news-events/press-releases/detail/87/vyome-reports-transformational-2025-results-company-well-positioned-for-breakout-phase https://ir.vyometx.com/news-events/press-releases/detail/88/livechain-completes-acquisition-of-senior-secured-debt-of-humanyze-an-mit-incubated-ai-enabled-hr-analytics-company Tue, 24 Feb 26 08:00:00 -0500 https://ir.vyometx.com/news-events/press-releases/detail/88/livechain-completes-acquisition-of-senior-secured-debt-of-humanyze-an-mit-incubated-ai-enabled-hr-analytics-company